ClinicalTrials.Veeva

Menu

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

Hengrui Medicine logo

Hengrui Medicine

Status and phase

Enrolling
Phase 3

Conditions

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Treatments

Drug: SHR-A1811
Drug: Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan

Study type

Interventional

Funder types

Industry

Identifiers

NCT06123494
SHR-A1811-308

Details and patient eligibility

About

This study will assess the efficacy and safety of SHR-A1811 compared with treatment chosen by the investigator in participants with HER2-positive (defined as immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+) gastric or GEJ adenocarcinoma (based on [American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines who have progressed on or after a first-line anti-HER2 therapy-containing regimen.

Enrollment

360 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age 18-75 years old, male and female;
  2. Histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma, and unresectable locally advanced or metastatic disease
  3. Prior anti-HER-2 containing treatment
  4. Progression on or after first-line standard treatment (Prior neoadjuvant or adjuvant therapy can be counted as a line of therapy if the subject progressed on or within 6 months of completing neoadjuvant or adjuvant therapy);
  5. Centrally confirmed HER2-positive (IHC 3+ or IHC 2+ and evidence of HER2 amplification by ISH) as classified by ASCO-CAP on a tumor biopsy
  6. At least one measurable lesion according to the solid tumor response Evaluation Criteria (RECIST 1.1);
  7. ECOG: 0-1;
  8. Expected survival ≥12 weeks;
  9. Good blood reserve and liver, kidney and coagulation function;
  10. Willing to provide informed consent for study participation.

Exclusion criteria

  1. Receive the last dose of anti-cancer therapy(including chemotherapy, radiotherapy, biological therapy, targeted therapy or immunotherapy) within 4 weeks, prior to the first dose;
  2. Known allergies to monoclonal antibodies and inactive ingredients of this product, and allergies to paclitaxel, docetaxel, and irinotecan concurrently;
  3. The toxicity of prior anti-tumor therapy did not recover to the level specified by CTCAE v5.0 grade evaluation ≤ Grade 1 or inclusion/exclusion criteria;
  4. Clinically active central nervous system metastases;
  5. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring repeated drainage;
  6. Clinically significant gastrointestinal disorder by the opinion of Investigator;
  7. Has a history of immunodeficiency, including a positive HIV test;
  8. During the screening visits and before the first dose, unexplained fever > 38.5℃, severe infection (CTC-AE > Grade 2), and active pulmonary inflammation were indicated by screening imaging;
  9. Subjects with interstitial pneumonia or with ≥ grade 3 interstitial pneumonia during prior treatment with immune checkpoint inhibitors;
  10. Active hepatitis B(HBV DNA ≥ 500 IU/mL), hepatitis C (positive for hepatitis C antibody, and HCV-RNA above the lower limit of detection of the analytical method);
  11. Clinically significant cardiovascular disease ,such as severe/unstable angina, symptomatic congestive heart failure (NYHA ≥ Class II.), clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention, myocardial infarction within 6 months before the first dose, cerebrovascular accident (including transient ischemic attack); QTcF of 12-lead ECG was ≥470 ms; Left ventricular ejection fraction <50%; Clinically uncontrolled hypertension;
  12. Had other malignancies with 5 years;
  13. Pregnant or lactating women;
  14. Other factors that might have led to drop out the study by the investigator opinion.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

360 participants in 2 patient groups

SHR-A1811
Experimental group
Treatment:
Drug: SHR-A1811
The investigators' choice
Active Comparator group
Treatment:
Drug: Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan

Trial contacts and locations

1

Loading...

Central trial contact

Yang Wu

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems